In a phase 2 trial of 88 older adults with newly diagnosed DLBCL unfit for anthracyclines, complete response was 63.6% with epcoritamab alone vs 45.5% with epcoritamab plus lenalidomide; serious adverse events 64% vs 81%. Monotherapy went forward to expansion.
RCTn = 111
Vitolo et al. Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial